Clinical Trials
629 trialsNeoB-Cap1
Novartis
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Novartis
RAINFOL-01
Genmab
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Boehringer Ingelheim
Vaccination With Flt3L, Radiation, and Poly-ICLC
Icahn School of Medicine at Mount Sinai
PIKALO-1
Eli Lilly and Company
ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC
Dana-Farber Cancer Institute
MK-1022-009
Merck Sharp & Dohme LLC
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Terremoto Biosciences Inc.
LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast Cancer
Integro Theranostics
[18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer
University of Washington
BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder
University of Illinois at Chicago
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
AstraZeneca
MoonROSE
Genentech, Inc.
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
BioNTech SE
A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer
Memorial Sloan Kettering Cancer Center
Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
Cybrexa Therapeutics
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
Aminex Therapeutics, Inc.
Oral Zn-Telomir Monotherapy in Patients With Advanced or Metastatic Triple-Negative Breast Cancer (TNBC)
Telomir Pharmaceuticals, Inc.
MK-2870-001
Klus Pharma Inc.
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...
National Institutes of Health Clinical Center (CC)
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C)
Pfizer
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
ModeX Therapeutics, An OPKO Health Company
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Ensem Therapeutics
Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Novartis
CERTIS1
AstraZeneca
VS-6766+Abema+Fulv in Met HR+/HER- BC
Dana-Farber Cancer Institute
Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer
Faeth Therapeutics
A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Breast Cancer
Akeso
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Novartis
Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer
Providence Health & Services
BEGONIA
AstraZeneca
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
Astellas Pharma Inc
JAZMINE
MedSIR
A Study of Multiparametric MRI and pHLIP® ICG in Breast Cancer Imaging During Surgery
Memorial Sloan Kettering Cancer Center
Amelia-1
SynDevRx, Inc.
PIKHER2
Institut Paoli-Calmettes
TAKTIC
Institut Paoli-Calmettes
A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer
Pfizer
MEDIOLA
AstraZeneca
Breast Cancer Study of Preoperative Pembrolizumab + Radiation
Cedars-Sinai Medical Center
Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis
Washington University School of Medicine
Effect of High Dose Vitamin D on Cancer Biomarkers and Breast Cancer Tumors
University of Miami
ART
Weill Medical College of Cornell University
LIBRETTO-001
Eli Lilly and Company
Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer
Memorial Sloan Kettering Cancer Center
mBC
Arvinas Inc.
Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer.
BioLite, Inc.
Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer
Icahn School of Medicine at Mount Sinai